Patients with mild, infrequent asthma symptoms may require only intermittent, as needed use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740).
轻度、偶发哮喘症状的患者可能仅需根据需要间歇性使用吸入型短效β2肾上腺素能激动剂。除运动诱发性支气管痉挛外,每周使用短效β2激动剂超过两次表明需要进行抗炎治疗。吸入性糖皮质激素是最有效的抗炎药物;白三烯调节剂是效果稍逊的替代药物。如果低剂量规律使用吸入性糖皮质激素不能预防症状,应加用长效β2激动剂;加用第二种药物比增加吸入性糖皮质激素剂量更有效。白三烯调节剂也可作为第二种药物使用。对于12岁以上经其他药物治疗无法控制的过敏性哮喘患者,可考虑使用奥马珠单抗作为辅助治疗。短期口服糖皮质激素可能对急性加重期有效。本文不包括作为医疗急症的急性重症哮喘的治疗;其他地方已有相关综述(ER McFadden Jr,《美国呼吸与危重症医学杂志》2003年;168:740)。